Toward a therapeutic reduction of imatinib refractory myeloproliferative neoplasm-initiating cells.

about

Integrated analysis identifies interaction patterns between small molecules and pathways

P2860

Q33999789-41FA2232-F2DD-428B-969B-B98A8712067C

P2860

Toward a therapeutic reduction of imatinib refractory myeloproliferative neoplasm-initiating cells.

Item

http://www.wikidata.org/entity/Q38311168

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Toward a therapeutic reduction ...... ive neoplasm-initiating cells.

@en

type

Item

label

Toward a therapeutic reduction ...... ive neoplasm-initiating cells.

@en

prefLabel

Toward a therapeutic reduction ...... ive neoplasm-initiating cells.

@en

P1476

Toward a therapeutic reduction ...... ive neoplasm-initiating cells.

@en

P2093

K I Oravecz-Wilson

http://www.w3.org/2001/XMLSchema#string

S B Foley

http://www.w3.org/2001/XMLSchema#string

S T Philips

http://www.w3.org/2001/XMLSchema#string

V E Mgbemena

http://www.w3.org/2001/XMLSchema#string

Z L Hildenbrand

http://www.w3.org/2001/XMLSchema#string

P2860

Carboxypeptidase A3 (CPA3): a novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cells

CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis

Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.

Molecular signatures of quiescent, mobilized and leukemia-initiating hematopoietic stem cells.

Phylogenetic analysis of the MS4A and TMEM176 gene families

Core-binding factor (CBF) and MLL-associated primary acute myeloid leukemia: biology and clinical implications.

Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate.

P2888

onc.2013.484

P304

5379-5390

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/ONC.2013.484

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Theodora S. Ross

P577

2013-11-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258636108

http://www.w3.org/2001/XMLSchema#string

P6179

1002472871

http://www.w3.org/2001/XMLSchema#string

P698

24240679

http://www.w3.org/2001/XMLSchema#string

P932

4025985

http://www.w3.org/2001/XMLSchema#string

Toward a therapeutic reduction of imatinib refractory myeloproliferative neoplasm-initiating cells.

about

P2860

P2860

Toward a therapeutic reduction of imatinib refractory myeloproliferative neoplasm-initiating cells.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P6179

P698

P932